Osteoporosis Drugs Market: Global Industry Analysis And Forecast (2022-2029)


Osteoporosis Drugs Market is expected to grow at a CAGR of 3.45% during the forecast period and the market size is expected to reach nearly US$ 11.61 Bn by 2029.

Osteoporosis Drugs Market

To know about the Research Methodology:-Request Free Sample Report

Osteoporosis is a condition in which the bones become weak and fragile due to the loss of tissue. This condition can arise due to hormonal changes, the deficiency of calcium or vitamin.Global Osteoporosis Market is driven by factors such as an increasing geriatric population & post-menopausal women, increasing prevalent cases of osteoporosis in younger population, risk of hip, forearm, and spine fractures, increasing expenditures in R&D for new and innovative drug formulation.

However, factors such as the side-effects and adverse reactions by osteoporotic drugs, issues in regulatory approval for drugs and lesser public awareness are restraining the growth of the osteoporosis drugs market.By drug class, the osteoporosis drugs market is segmented into bisphosphonates, parathyroid hormone therapy, selective estrogen receptor modulator (SERM), rank ligand inhibitor, and calcitonin. Among these, the bisphosphonates segment is expected to exhibit highest market share at a CAGR of xx% over forecast period. Whereas, the rank ligand inhibitor drug class category is expected to grow at a highest CAGR over forecast period.

By geography Global Osteoporosis Market is segmented into North America, APAC, Europe, MEA & Africa and Latin America. North America is expected to exhibit highest market share at a CAGR of xx% over forecast period. Several collaborative efforts undertaken by major companies to enhance their R&D capabilities and ensure high medical standards are expected to propel the market across this region. Additionally, the majority share can also be attributed to the high disease burden in this region. Moreover, Asia Pacific region is expected to grow at a highest CAGR over forecast period.

Key players operating in this market are Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., Ltd., and GlaxoSmithKline plc. Novartis International AG, Merck & Co. Inc., Amgen Inc., and Radius Health Inc. the intensity of rivalry among these players is high. These players are also trying to improve their position in the market and enhancing their regional presence by undergoing mergers and acquisitions, strategic alliances, new product launches, expansion etc.

Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the Global Osteoporosis Market. The report encompasses the market by different segments and regions, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics and future opportunities that might exist in the Global Osteoporosis Market. The driving forces, as well as considerable restraints, have been explained in depth. In addition to this, competitive landscape describing the strategic growth of the competitors has been taken into consideration for enhancing market know-how of our clients and at the same time explain Global Osteoporosis Market positioning of competitors.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Osteoporosis Market Scope: Inquire before buying


Osteoporosis Market Segmentation by Drug Class

• Bisphosphonates
• Selective Estrogen Inhibitors Modulator (SERM)
• Parathyroid Hormone Therapy
• Calcitonin
• Rank Ligand Inhibitors
• Branded
• Generics
• Others

Osteoporosis Market Segmentation by Gender

• Male
• Female

Osteoporosis Market Segmentation by Route of Administration

• Oral
• Injectable
• Others

Osteoporosis Market Segmentation by Region

• APAC
• North America
• Europe
• MEA& Africa
• Latin America

Osteoporosis Drugs Market Key Players

• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Novartis International AG
• Merck & Co. Inc.
• Amgen Inc.
• Radius Health Inc.
• Novo Nordisk A/S
• Actavis plc
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Allergan plc
• Sanofi S.A.
• Abiogen Pharma S.p.A.
• Merrion Pharmaceuticals Plc.

Frequently Asked Questions:

1. Which region has the largest share in Global Osteoporosis Drugs Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Osteoporosis Drugs Market?
Ans: The Global Osteoporosis Drugs Market is growing at a CAGR of 3.45% during forecasting period 2022-2029.

3. What is scope of the Global Osteoporosis Drugs market report?
Ans: Global Osteoporosis Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Osteoporosis Drugs market?
Ans: The important key players in the Global Osteoporosis Drugs Market are – Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Novo Nordisk A/S, Actavis plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Allergan plc, Sanofi S.A., Abiogen Pharma S.p.A., and Merrion Pharmaceuticals Plc.

5. What is the study period of this market?
Ans: The Global Osteoporosis Drugs Market is studied from 2021 to 2029. 




Global Osteoporosis Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.2. Secondary data
2.3.3. Secondary Sources
2.3.4. Primary Research
2.3.5. Data from Primary Sources
2.3.6. Breakdown of Primary Sources

3. Executive Summary: Global Osteoporosis Drugs Market, by Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Osteoporosis Drugs Market Analysis and Forecast
6.1. Global Osteoporosis Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Osteoporosis Drugs Market Analysis and Forecast, By Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Osteoporosis Drugs Market Value Share Analysis, By Drug Class
7.4. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, By Drug Class
7.5. Global Osteoporosis Drugs Market Analysis, By Drug Class
7.6. Global Osteoporosis Drugs Market Attractiveness Analysis, By Drug Class

8. Global Osteoporosis Drugs Market Analysis and Forecast, By Gender
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Osteoporosis Drugs Market Value Share Analysis, By Gender
8.4. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, By Gender
8.5. Global Osteoporosis Drugs Market Analysis, By Gender
8.6. Global Osteoporosis Drugs Market Attractiveness Analysis, By Gender

9. Global Osteoporosis Drugs Market Analysis and Forecast, by Route of Administration
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Osteoporosis Drugs Market Value Share Analysis, by Route of Administration
9.4. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, by Route of Administration
9.5. Global Osteoporosis Drugs Market Analysis, by Route of Administration
9.6. Global Osteoporosis Drugs Market Attractiveness Analysis, by Route of Administration

10. Global Osteoporosis Drugs Market Analysis, by Region
10.1. Global Osteoporosis Drugs Market Value Share Analysis, by Region
10.2. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, by Region
10.3. Global Osteoporosis Drugs Market Attractiveness Analysis, by Region

11. North America Osteoporosis Drugs Market Analysis
11.1. Key Findings
11.2. North America Osteoporosis Drugs Market Overview
11.3. North America Osteoporosis Drugs Market Value Share Analysis, By Drug Class
11.4. North America Osteoporosis Drugs Market Forecast, By Drug ClasS
11.4.1. Bisphosphonates
11.4.2. Selective Estrogen Inhibitors Modulator (SERM)
11.4.3. Parathyroid Hormone Therapy
11.4.4. Calcitonin
11.4.5. Rank Ligand Inhibitors
11.4.6. Branded
11.4.7. Generics
11.4.8. Others
11.5. North America Osteoporosis Drugs Market Value Share Analysis, By Gender
11.6. North America Osteoporosis Drugs Market Forecast, By Gender
11.6.1. Male
11.6.2. Female
11.7. North America Osteoporosis Drugs Market Value Share Analysis, by Route of Administration
11.8. North America Osteoporosis Drugs Market Forecast, by Route of Administration
11.8.1. Oral
11.8.2. Injectable
11.8.3. Others
11.9. North America Osteoporosis Drugs Market Value Share Analysis, by Country
11.10. North America Osteoporosis Drugs Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Osteoporosis Drugs Market Analysis, by Country
11.12. U.S. Osteoporosis Drugs Market Forecast, By Drug Class
11.12.1. Bisphosphonates
11.12.2. Selective Estrogen Inhibitors Modulator (SERM)
11.12.3. Parathyroid Hormone Therapy
11.12.4. Calcitonin
11.12.5. Rank Ligand Inhibitors
11.12.6. Branded
11.12.7. Generics
11.12.8. Others
11.13. U.S. Osteoporosis Drugs Market Forecast, By Gender
11.13.1. Male
11.13.2. Female
11.14. U.S. Osteoporosis Drugs Market Forecast, by Route of Administration
11.14.1. Oral
11.14.2. Injectable
11.14.3. Others
11.15. Canada Osteoporosis Drugs Market Forecast, By Drug Class
11.15.1. Bisphosphonates
11.15.2. Selective Estrogen Inhibitors Modulator (SERM)
11.15.3. Parathyroid Hormone Therapy
11.15.4. Calcitonin
11.15.5. Rank Ligand Inhibitors
11.15.6. Branded
11.15.7. Generics
11.15.8. Others
11.16. Canada Osteoporosis Drugs Market Forecast, By Gender
11.16.1. Male
11.16.2. Female
11.17. Canada Osteoporosis Drugs Market Forecast, by Route of Administration
11.17.1. Oral
11.17.2. Injectable
11.17.3. Others
11.18. North America Osteoporosis Drugs Market Attractiveness Analysis
11.18.1. By Drug Class
11.18.2. By Gender
11.18.3. By Route of Administration
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Development

12. Europe Osteoporosis Drugs Market Analysis
12.1. Key Findings
12.2. Europe Osteoporosis Drugs Market Overview
12.3. Europe Osteoporosis Drugs Market Value Share Analysis, By Drug Class
12.4. Europe Osteoporosis Drugs Market Forecast, By Drug Class
12.4.1. Bisphosphonates
12.4.2. Selective Estrogen Inhibitors Modulator (SERM)
12.4.3. Parathyroid Hormone Therapy
12.4.4. Calcitonin
12.4.5. Rank Ligand Inhibitors
12.4.6. Branded
12.4.7. Generics
12.4.8. Others
12.5. Europe Osteoporosis Drugs Market Value Share Analysis, By Gender
12.6. Europe Osteoporosis Drugs Market Forecast, By Gender
12.6.1. Male
12.6.2. Female
12.7. Europe Osteoporosis Drugs Market Value Share Analysis, by Route of Administration
12.8. Europe Osteoporosis Drugs Market Forecast, by Route of Administration
12.8.1. Oral
12.8.2. Injectable
12.8.3. Others
12.9. Europe Osteoporosis Drugs Market Value Share Analysis, by Country
12.10. Europe Osteoporosis Drugs Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Osteoporosis Drugs Market Analysis, by Country
12.12. Germany Osteoporosis Drugs Market Forecast, By Drug Class
12.12.1. Bisphosphonates
12.12.2. Selective Estrogen Inhibitors Modulator (SERM)
12.12.3. Parathyroid Hormone Therapy
12.12.4. Calcitonin
12.12.5. Rank Ligand Inhibitors
12.12.6. Branded
12.12.7. Generics
12.12.8. Others
12.13. Germany Osteoporosis Drugs Market Forecast, By Gender
12.13.1. Male
12.13.2. Female
12.14. Germany Osteoporosis Drugs Market Forecast, by Route of Administration
12.14.1. Oral
12.14.2. Injectable
12.14.3. Others
12.15. U.K. Osteoporosis Drugs Market Forecast, By Drug Class
12.15.1. Bisphosphonates
12.15.2. Selective Estrogen Inhibitors Modulator (SERM)
12.15.3. Parathyroid Hormone Therapy
12.15.4. Calcitonin
12.15.5. Rank Ligand Inhibitors
12.15.6. Branded
12.15.7. Generics
12.15.8. Others
12.16. U.K. Osteoporosis Drugs Market Forecast, By Gender
12.16.1. Male
12.16.2. Female
12.17. U.K. Osteoporosis Drugs Market Forecast, by Route of Administration
12.17.1. Oral
12.17.2. Injectable
12.17.3. Others
12.18. France Osteoporosis Drugs Market Forecast, By Drug Class
12.18.1. Bisphosphonates
12.18.2. Selective Estrogen Inhibitors Modulator (SERM)
12.18.3. Parathyroid Hormone Therapy
12.18.4. Calcitonin
12.18.5. Rank Ligand Inhibitors
12.18.6. Branded
12.18.7. Generics
12.18.8. Others
12.19. France Osteoporosis Drugs Market Forecast, By Gender
12.19.1. Male
12.19.2. Female
12.20. France Osteoporosis Drugs Market Forecast, by Route of Administration
12.20.1. Oral
12.20.2. Injectable
12.20.3. Others
12.21. Italy Osteoporosis Drugs Market Forecast, By Drug Class
12.21.1. Bisphosphonates
12.21.2. Selective Estrogen Inhibitors Modulator (SERM)
12.21.3. Parathyroid Hormone Therapy
12.21.4. Calcitonin
12.21.5. Rank Ligand Inhibitors
12.21.6. Branded
12.21.7. Generics
12.21.8. Others
12.22. Italy Osteoporosis Drugs Market Forecast, By Gender
12.22.1. Male
12.22.2. Female
12.23. Italy Osteoporosis Drugs Market Forecast, by Route of Administration
12.23.1. Oral
12.23.2. Injectable
12.23.3. Others
12.24. Spain Osteoporosis Drugs Market Forecast, By Drug Class
12.24.1. Bisphosphonates
12.24.2. Selective Estrogen Inhibitors Modulator (SERM)
12.24.3. Parathyroid Hormone Therapy
12.24.4. Calcitonin
12.24.5. Rank Ligand Inhibitors
12.24.6. Branded
12.24.7. Generics
12.24.8. Others
12.25. Spain Osteoporosis Drugs Market Forecast, By Gender
12.25.1. Male
12.25.2. Female
12.26. Spain Osteoporosis Drugs Market Forecast, by Route of Administration
12.26.1. Oral
12.26.2. Injectable
12.26.3. Others
12.27. Rest of Europe Osteoporosis Drugs Market Forecast, By Drug Class
12.27.1. Bisphosphonates
12.27.2. Selective Estrogen Inhibitors Modulator (SERM)
12.27.3. Parathyroid Hormone Therapy
12.27.4. Calcitonin
12.27.5. Rank Ligand Inhibitors
12.27.6. Branded
12.27.7. Generics
12.27.8. Others
12.28. Rest of Europe Osteoporosis Drugs Market Forecast, By Gender
12.28.1. Male
12.28.2. Female
12.29. Rest of Europe Osteoporosis Drugs Market Forecast, by Route of Administration
12.29.1. Oral
12.29.2. Injectable
12.29.3. Others
12.30. Europe Osteoporosis Drugs Market Attractiveness Analysis
12.30.1. By Drug Class
12.30.2. By Gender
12.30.3. By Route of Administration
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Development

13. Asia Pacific Osteoporosis Drugs Market Analysis
13.1. Key Findings
13.2. Asia Pacific Osteoporosis Drugs Market Overview
13.3. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, By Drug Class
13.4. Asia Pacific Osteoporosis Drugs Market Forecast, By Drug Class
13.4.1. Bisphosphonates
13.4.2. Selective Estrogen Inhibitors Modulator (SERM)
13.4.3. Parathyroid Hormone Therapy
13.4.4. Calcitonin
13.4.5. Rank Ligand Inhibitors
13.4.6. Branded
13.4.7. Generics
13.4.8. Others
13.5. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, By Gender
13.6. Asia Pacific Osteoporosis Drugs Market Forecast, By Gender
13.6.1. Male
13.6.2. Female
13.7. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, by Route of Administration
13.8. Asia Pacific Osteoporosis Drugs Market Forecast, by Route of Administration
13.8.1. Oral
13.8.2. Injectable
13.8.3. Others
13.9. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, by Country
13.10. Asia Pacific Osteoporosis Drugs Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Osteoporosis Drugs Market Analysis, by Country
13.12. China Osteoporosis Drugs Market Forecast, By Drug Class
13.12.1. Bisphosphonates
13.12.2. Selective Estrogen Inhibitors Modulator (SERM)
13.12.3. Parathyroid Hormone Therapy
13.12.4. Calcitonin
13.12.5. Rank Ligand Inhibitors
13.12.6. Branded
13.12.7. Generics
13.12.8. Others
13.13. China Osteoporosis Drugs Market Forecast, By Gender
13.13.1. Male
13.13.2. Female
13.14. China Osteoporosis Drugs Market Forecast, by Route of Administration
13.14.1. Oral
13.14.2. Injectable
13.14.3. Others
13.15. India Osteoporosis Drugs Market Forecast, By Drug Class
13.15.1. Bisphosphonates
13.15.2. Selective Estrogen Inhibitors Modulator (SERM)
13.15.3. Parathyroid Hormone Therapy
13.15.4. Calcitonin
13.15.5. Rank Ligand Inhibitors
13.15.6. Branded
13.15.7. Generics
13.15.8. Others
13.16. India Osteoporosis Drugs Market Forecast, By Gender
13.16.1. Male
13.16.2. Female
13.17. India Osteoporosis Drugs Market Forecast, by Route of Administration
13.17.1. Oral
13.17.2. Injectable
13.17.3. Others
13.18. Japan Osteoporosis Drugs Market Forecast, By Drug Class
13.18.1. Bisphosphonates
13.18.2. Selective Estrogen Inhibitors Modulator (SERM)
13.18.3. Parathyroid Hormone Therapy
13.18.4. Calcitonin
13.18.5. Rank Ligand Inhibitors
13.18.6. Branded
13.18.7. Generics
13.18.8. Others
13.19. Japan Osteoporosis Drugs Market Forecast, By Gender
13.19.1. Male
13.19.2. Female
13.20. Japan Osteoporosis Drugs Market Forecast, by Route of Administration
13.20.1. Oral
13.20.2. Injectable
13.20.3. Others
13.21. ASEAN Osteoporosis Drugs Market Forecast, By Drug Class
13.21.1. Bisphosphonates
13.21.2. Selective Estrogen Inhibitors Modulator (SERM)
13.21.3. Parathyroid Hormone Therapy
13.21.4. Calcitonin
13.21.5. Rank Ligand Inhibitors
13.21.6. Branded
13.21.7. Generics
13.21.8. Others
13.22. ASEAN Osteoporosis Drugs Market Forecast, By Gender
13.22.1. Male
13.22.2. Female
13.23. ASEAN Osteoporosis Drugs Market Forecast, by Route of Administration
13.23.1. Oral
13.23.2. Injectable
13.23.3. Others
13.24. Rest of Asia Pacific Osteoporosis Drugs Market Forecast, By Drug Class
13.24.1. Bisphosphonates
13.24.2. Selective Estrogen Inhibitors Modulator (SERM)
13.24.3. Parathyroid Hormone Therapy
13.24.4. Calcitonin
13.24.5. Rank Ligand Inhibitors
13.24.6. Branded
13.24.7. Generics
13.24.8. Others
13.25. Rest of Asia Pacific Osteoporosis Drugs Market Forecast, By Gender
13.25.1. Male
13.25.2. Female
13.26. Rest of Asia Pacific Osteoporosis Drugs Market Forecast, by Route of Administration
13.26.1. Oral
13.26.2. Injectable
13.26.3. Others
13.27. Asia Pacific Osteoporosis Drugs Market Attractiveness Analysis
13.27.1. By Drug Class
13.27.2. By Gender
13.27.3. By Route of Administration
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Development

14. Middle East & Africa Osteoporosis Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Osteoporosis Drugs Market Overview
14.3. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, By Drug Class
14.4. Middle East & Africa Osteoporosis Drugs Market Forecast, By Drug Class
14.4.1. Bisphosphonates
14.4.2. Selective Estrogen Inhibitors Modulator (SERM)
14.4.3. Parathyroid Hormone Therapy
14.4.4. Calcitonin
14.4.5. Rank Ligand Inhibitors
14.4.6. Branded
14.4.7. Generics
14.4.8. Others
14.5. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, By Gender
14.6. Middle East & Africa Osteoporosis Drugs Market Forecast, By Gender
14.6.1. Male
14.6.2. Female
14.7. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, by Route of Administration
14.8. Middle East & Africa Osteoporosis Drugs Market Forecast, by Route of Administration
14.8.1. Oral
14.8.2. Injectable
14.8.3. Others
14.9. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, by Country
14.10. Middle East & Africa Osteoporosis Drugs Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Osteoporosis Drugs Market Analysis, by Country
14.12. GCC Osteoporosis Drugs Market Forecast, By Drug Class
14.12.1. Bisphosphonates
14.12.2. Selective Estrogen Inhibitors Modulator (SERM)
14.12.3. Parathyroid Hormone Therapy
14.12.4. Calcitonin
14.12.5. Rank Ligand Inhibitors
14.12.6. Branded
14.12.7. Generics
14.12.8. Others
14.13. GCC Osteoporosis Drugs Market Forecast, By Gender
14.13.1. Male
14.13.2. Female
14.14. GCC Osteoporosis Drugs Market Forecast, by Route of Administration
14.14.1. Oral
14.14.2. Injectable
14.14.3. Others
14.15. South Africa Osteoporosis Drugs Market Forecast, By Drug Class
14.15.1. Bisphosphonates
14.15.2. Selective Estrogen Inhibitors Modulator (SERM)
14.15.3. Parathyroid Hormone Therapy
14.15.4. Calcitonin
14.15.5. Rank Ligand Inhibitors
14.15.6. Branded
14.15.7. Generics
14.15.8. Others
14.16. South Africa Osteoporosis Drugs Market Forecast, By Gender
14.16.1. Male
14.16.2. Female
14.17. South Africa Osteoporosis Drugs Market Forecast, by Route of Administration
14.17.1. Oral
14.17.2. Injectable
14.17.3. Others
14.18. Rest of Middle East & Africa Osteoporosis Drugs Market Forecast, By Drug Class
14.18.1. Bisphosphonates
14.18.2. Selective Estrogen Inhibitors Modulator (SERM)
14.18.3. Parathyroid Hormone Therapy
14.18.4. Calcitonin
14.18.5. Rank Ligand Inhibitors
14.18.6. Branded
14.18.7. Generics
14.18.8. Others
14.19. Rest of Middle East & Africa Osteoporosis Drugs Market Forecast, By Gender
14.19.1. Male
14.19.2. Female
14.20. Rest of Middle East & Africa Osteoporosis Drugs Market Forecast, by Route of Administration
14.20.1. Oral
14.20.2. Injectable
14.20.3. Others
14.21. Middle East & Africa Osteoporosis Drugs Market Attractiveness Analysis
14.21.1. By Drug Class
14.21.2. By Gender
14.21.3. By Route of Administration
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Development

15. South America Osteoporosis Drugs Market Analysis
15.1. Key Findings
15.2. South America Osteoporosis Drugs Market Overview
15.3. South America Osteoporosis Drugs Market Value Share Analysis, By Drug Class
15.4. South America Osteoporosis Drugs Market Forecast, By Drug Class
15.4.1. Bisphosphonates
15.4.2. Selective Estrogen Inhibitors Modulator (SERM)
15.4.3. Parathyroid Hormone Therapy
15.4.4. Calcitonin
15.4.5. Rank Ligand Inhibitors
15.4.6. Branded
15.4.7. Generics
15.4.8. Others
15.5. South America Osteoporosis Drugs Market Value Share Analysis, By Gender
15.6. South America Osteoporosis Drugs Market Forecast, By Gender
15.6.1. Male
15.6.2. Female
15.7. South America Osteoporosis Drugs Market Value Share Analysis, by Route of Administration
15.8. South America Osteoporosis Drugs Market Forecast, by Route of Administration
15.8.1. Oral
15.8.2. Injectable
15.8.3. Others
15.9. South America Osteoporosis Drugs Market Value Share Analysis, by Country
15.10. South America Osteoporosis Drugs Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Osteoporosis Drugs Market Analysis, by Country
15.12. Brazil Osteoporosis Drugs Market Forecast, By Drug Class
15.12.1. Bisphosphonates
15.12.2. Selective Estrogen Inhibitors Modulator (SERM)
15.12.3. Parathyroid Hormone Therapy
15.12.4. Calcitonin
15.12.5. Rank Ligand Inhibitors
15.12.6. Branded
15.12.7. Generics
15.12.8. Others
15.13. Brazil Osteoporosis Drugs Market Forecast, By Gender
15.13.1. Male
15.13.2. Female
15.14. Brazil Osteoporosis Drugs Market Forecast, by Route of Administration
15.14.1. Oral
15.14.2. Injectable
15.14.3. Others
15.15. Mexico Osteoporosis Drugs Market Forecast, By Drug Class
15.15.1. Bisphosphonates
15.15.2. Selective Estrogen Inhibitors Modulator (SERM)
15.15.3. Parathyroid Hormone Therapy
15.15.4. Calcitonin
15.15.5. Rank Ligand Inhibitors
15.15.6. Branded
15.15.7. Generics
15.15.8. Others
15.16. Mexico Osteoporosis Drugs Market Forecast, By Gender
15.16.1. Male
15.16.2. Female
15.17. Mexico Osteoporosis Drugs Market Forecast, by Route of Administration
15.17.1. Oral
15.17.2. Injectable
15.17.3. Others
15.18. Rest of South America Osteoporosis Drugs Market Forecast, By Drug Class
15.18.1. Bisphosphonates
15.18.2. Selective Estrogen Inhibitors Modulator (SERM)
15.18.3. Parathyroid Hormone Therapy
15.18.4. Calcitonin
15.18.5. Rank Ligand Inhibitors
15.18.6. Branded
15.18.7. Generics
15.18.8. Others
15.19. Rest of South America Osteoporosis Drugs Market Forecast, By Gender
15.19.1. Male
15.19.2. Female
15.20. Rest of South America Osteoporosis Drugs Market Forecast, by Route of Administration
15.20.1. Oral
15.20.2. Injectable
15.20.3. Others
15.21. South America Osteoporosis Drugs Market Attractiveness Analysis
15.21.1. By Drug Class
15.21.2. By Gender
15.21.3. By Route of Administration
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Development

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Eli Lilly and Company
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Company Footprint
16.3.2. Pfizer Inc.
16.3.3. F. Hoffmann-La Roche
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. GlaxoSmithKline plc.
16.3.6. Novartis International AG
16.3.7. Merck & Co. Inc.
16.3.8. Amgen Inc.
16.3.9. Radius Health Inc.
16.3.10. Novo Nordisk A/S
16.3.11. Actavis plc
16.3.12. Sun Pharmaceutical Industries Ltd.
16.3.13. Takeda Pharmaceutical Company Limited
16.3.14. Allergan plc
16.3.15. Sanofi S.A.
16.3.16. Abiogen Pharma S.p.A.
16.3.17. Merrion Pharmaceuticals Plc.

17. Primary Key Insights
  • INQUIRE BEFORE BUYING